Lion Biotechnologies, Inc. Changes Name to Iovance Biotherapeutics, Inc.
June 27 2017 - 8:00AM
Name change reflects company’s focus in advancing
the field of immuno-oncology
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that it changed its corporate name from Lion Biotechnologies, Inc.
to Iovance Biotherapeutics, Inc. The company’s new NASDAQ ticker
symbol “IOVA” will be effective at the open of the market on June
28, 2017. The former ticker symbol “LBIO” will remain effective
through the market close today, June 27, 2017. The new website for
Iovance Biotherapeutics is www.iovance.com.
“Our new name better represents our leadership in the field of
immuno-oncology and reflects the strong progress we have made since
we laid out our revised business plan last year. Our robust
pipeline based on our TIL technology, partnerships with leading
institutions and strides in manufacturing demonstrates our
commitment to rapidly developing therapies that will change the
lives of patients with solid tumors,” said Dr. Maria Fardis, PhD,
MBA, Chief Executive Officer of Iovance Biotherapeutics.
As the company prepares to expand its clinical trials into
Europe, with a planned submission to European health authorities in
the second half of 2017, this name change allows the company the
opportunity to develop a strong and unique global brand that
reflects the recent advancements in evaluating TIL therapy in new
indications.
About Iovance Biotherapeutics, Inc. (formerly
Lion Biotechnologies, Inc.)Iovance Biotherapeutics, Inc. is a
clinical-stage biotechnology company focused on the development of
cancer immunotherapy products for the treatment of various cancers.
The Company's lead product candidate is an adoptive cell therapy
using tumor-infiltrating lymphocyte (TIL) technology being
investigated for the treatment of patients with refractory
metastatic melanoma, metastatic squamous cell carcinoma of the head
and neck and metastatic cervical carcinoma. For more information,
please visit http://www.iovance.com.
Forward-Looking Statements Certain matters
discussed in this press release are “forward-looking statements”.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. In particular, the
Company’s statements regarding trends and potential future results
are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties,
including, but not limited to, the success, timing and cost of our
ongoing clinical trials and anticipated clinical trials for our
current product candidates, including statements regarding the
timing of initiation and completion of the trials; the timing of
and our ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, our product candidates; the Company’s
ability to successfully defend its intellectual property or obtain
the necessary licenses at a cost acceptable to the Company, if at
all; the successful implementation of the Company’s research and
development programs and collaborations; the success of the
Company’s license agreements; the acceptance by the market of the
Company’s product candidates, if approved; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such
statements. A further list and description of the Company’s
risks, uncertainties and other factors can be found in the
Company’s most recent Annual Report on Form 10-K and the Company's
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov or
www.iovance.com. The forward-looking statements are made only as of
the date of this press release and the Company undertakes no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstance.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024